Administration of botulinum toxin in reserving the function of salivary gland in neck radiotherapy
Phase 2
Recruiting
- Conditions
- Malignant tumors of head and neck.Malignant neoplasm of head, face and neck
- Registration Number
- IRCT20180225038862N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Age older than 18 years
Exclusion Criteria
History of xerostomia
History of previous neck radiotherapy
History of collagen vascular disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Xerostomia. Timepoint: Xerostomia will be evaluated before starting radiotherapy and 6 months after finishing radiotherapy. Method of measurement: Xerostomia will be evaluated through scintigraphy of sub-mandibular gland.
- Secondary Outcome Measures
Name Time Method Constipation. Timepoint: Constipation will be evaluated before injection of toxin and 6 months after injection. Method of measurement: Constipation will be evaluated through history.